AbbVie Stock News

-        Updated indication allows the use of RINVOQ® (upadacitinib) prior to the use of tumor necrosis factor (TNF) blocking agents in patients for whom use of these treatments is clinically inadvisable and who have received at least one approved systemic therapy NORTH CHICAGO, Ill. , Oct. 13, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration (FDA) ...

Dividend stocks never go out of style, but they might be even more worthy of consideration right now because some evidence suggests that troubles lie ahead. The government shutdown and remaining uncertainty regarding tariffs could rock the economy or equity markets (or both).

New data from telisotuzumab adizutecan (Temab-A) and ABBV-706 across pancreatic, colorectal, and solid tumors, highlight progress in AbbVie's growing ADC portfolio designed to target difficult-to-treat cancers. NORTH CHICAGO, Ill.

Carolina Wealth Advisors, LLC disclosed in an Oct. 7, 2025, U.S. Securities and Exchange Commission filing that it sold 38,267 AbbVie shares for the quarter ended Sept. 30, 2025, an estimated $7.79 million trade based on quarterly average pricing.

By the makers of BOTOX® Cosmetic (onabotulinumtoxinA), SkinMedica®'s new packaging features a refreshed logo, modernized look, and luxe copper color palette. The brand's new HA5® moisturizer is designed to support the skin barrier and microbiome for bouncy, dewy, and soft skin.

Pfizer Inc. NYSE: PFE made a strong move higher after it became the first drug manufacturer to sign on as part of the TrumpRx platform. PFE stock is up nearly 14% since its closing price of around $23.61 on Sept.

Any pharmaceutical company as large and sprawling as AbbVie (ABBV 1.41%) never stops being busy, from pushing investigational drugs along the development pipeline to shipping blockbuster medications to pharmacies.

If x is good, isn't 2x even better? Usually. Granted, there can be too much of a good thing.